Avvisto Therapeutics
Cycloset
Cycloset® – a unique sympatholytic, dopamine agonist- insulin sensitizer, FDA Approved Product for the Treatment of Type 2 Diabetes
Science and Technology
Scores of pre-clinical and clinical studies manifested the FDA approval of Cycloset for Type 2 Diabetes. Click here to view selected peer-reviewed publications
Patient Information
Click here to view patient information for Cycloset for Type 2 Diabetes
Privacy Policy
Avvisto Therapeutics values your privacy